Chromogenic in situ hybirdization analysis of chromosomes 7,9, and 17 in pancreatic ductal adenocarcinoma based on tissue microarrays

Journal of B.U.ON.

Volumn 11, Issue 2, 2006, Pages 205-211

  Tsiambas, Evangelos ^a,e   Karameris, A ^a   Stamatelopoulos, A ^b   Baltayiannis, N ^b   Manaios, L ^a   Gerontopoulos, K ^a   Talieri, M ^c   Athanassiou, A E ^b   Patsouri, E ^d  

^a NIMTS HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e NONE   (Greece)

Author keywords

Chromogenic in situ hybridization; Chromosome instability; Pancreatic ductal adenocarcinoma; Tissue microarrays

Indexed keywords

PARAFFIN;

ADULT; ANEUPLOIDY; ARTICLE; CANCER CELL; CANCER GENETICS; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL POPULATION; CHI SQUARE TEST; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIPLOIDY; DISEASE COURSE; EMBEDDING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MONOSOMY; NUMERICAL CHROMOSOME ABERRATION; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS RESECTION; PANCREATICODUODENECTOMY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRUCTURAL CHROMOSOME ABERRATION; TISSUE MICROARRAY; AGED; CHROMOSOME ABERRATION; GENETICS; METHODOLOGY; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR;

AGED; CARCINOMA, PANCREATIC DUCTAL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 33751024818     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Alberston DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumours. Nat Genet 2003; 34; 369-376.
2. Wang S, Hossein Saboorian M, Frenkel EP et al. Aneusomy 17 in breast cancer: its role in HER2/neu protein expression and implication for clinical assessment of HER2/neu status. Mod Pathol 2002; 15: 137-145.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
4. Fauth C, Speicher MR. Classifying by colors: FISH-based genome analysis. Cytogenet Cell Genet 2001; 93: 1-10.
5. Soulie P, Fourme E, Hamelin R et al. Tp53 status and gene amplification in human colorectal carcinomas. Cancer Genet Cytogenet 1999; 115: 118-122.
6. Remvikos Y, Vogt N, Muleris M et al. DNA-repeat instability is associated with colorectal cancers presenting minimal chromosome rearrangements. Gene Chromosomes Cancer 1995; 12: 272-276.
7. Ruggeri BA, Huang L, Berger D et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm2 and p21/WAF-1 genes in sporadic and familial lesions. Cancer 1997; 79: 701-710.
8. Nakata B, Wang YQ, Yashiro M et al. Prognostic Value of Microsatellite Instability in Resectable Pancreatic Cancer. Clin Cancer Research 2002; 8: 2536-2540.
9. Rahman A, Wanzer D, Yeo CJ et al. A "catastrophic hypothesis" for pancreas cancer progression. Gastroenterology 2003; 124: 1958-1964.
10. Wei D, Xiong HQ, Abbruzzese JL, Xie K. Experimental animal models of pancreatic carcinogenesis and metastasis. Int J Gastrointest Cancer 2003; 33: 43-60.
11. Sohn TA, Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 2000; 9: 95-101.
12. Lemoine NR. Molecular advances in pancreatic cancer. Digestion 1997; 58: 550-556.
13. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26: 29-52.
14. Hashimoto K, Nio Y, Koike M et al. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome. Anticancer Res 2005; 25: 1361-1368.
15. Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993; 53: 5087-5089.
16. Heinmöller E, Dietmaier W, Zirngibl H. Molecular analysis of microdissected tumours, and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 2000; 157: 83-92.
17. Willenbucher RF, Aust DE, Chang CG et al. Genomic instability is an early event during the progression pathway of ulcerative colitis-related neoplasia. Am J Pathol 1999; 154: 1825-1830.
18. Yamamoto H, Itoh F, Nakamura H. Fukushima H. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001; 61: 3139-3144.
19. Moskovitz A, Linford N, Brentnall T et al. Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma. Genes Chromosomes Cancer 2003; 37: 201-206.
20. Stoeclein N, Luebke A, Erbesdoller A et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2004; 22: 4737-4745.
21. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 2000; 156: 2123-2133.
22. Brat DJ, Hahn SA, Griffin CA, Yeo CJ, Kern SE, Hruban RH. The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Am J Pathol 1997; 150: 383-391.
23. Nowak NJ, Gaile D, Conroy JM et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 2005; 161: 36-50.
24. Zhu J, Abbruzzese JL, Izzo J, Hittelman WN, Li D. AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 2005; 159: 10-17.
25. Aguirre AJ, Brennan C, Bailey G et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 2004; 101: 9067-9072.
26. Luttges J, Galehdari H, Brocker V et al. Allelic loss is often the first hit in the bi-allelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001; 158: 1677-1683.
27. Wiletz R, Argani P, Hruban R. Loss of heterozygosity or intragenic mutation? Which comes first? Am J Pathol 2001; 158: 1561-1564.
28. Tomaszewska R, Karcz D, Stachura J. An immunohistochemical study of the expression of bcl2 and p53 onceproteins in pancreatic intraepithelial neoplasia and pancreatic cancer. Int J Pancreatol 1999; 26: 163-171.
29. Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 2000; 7: 198-205.
30. Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res 2004; 10: 6598-6605.
31. Lebe B, Sagol O, Ulukus C et al. The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract 2004; 200: 389-396.
32. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol 2005; 18: 752-761.
33. Moroni M, Veronese S, Benventi S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
34. Tanner M, Gancberg D, Di Leo et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-1472.
35. Arnould L, Denoux Y, McGrogan G et al. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2/neu status in breast cancer. Br J Cancer 2003; 88: 1587-1591.
36. Simon R, Mirlacher M, Sauter G. Tissue microarrays in cancer diagnosis. Exp Rev Mol Diagn 2003; 3: 421-430.
37. Torhorst J, Bucher C, Kononen J et al. Tissue microarrays for rapid linking of molecular changes to clinical end points. Am J Pathol 2001; 159: 2249-2256.
38. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarrays sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002; 26: 312-319.
39. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949.